CoChat

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

Open access
Poschke, Isabel, Faryna, Marta, Bergmann, Frank, Flossdorf, Michael, Lauenstein, Claudia, Hermes, Jennifer, Hinz, Ulf, Hank, Thomas, Ehrenberg, Roland, Volkmar, Michael, Loewer, Martin, Glimm, Hanno, Hackert, Thilo, Sprick, Martin R., Höfer, Thomas, Trumpp, Andreas, Halama, Niels, Hassel, Jessica C., Strobel, Oliver, Büchler, Markus, Sahin, Ugur, Offringa, Rienk · 2016 · OncoImmunology
Cited by 100

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Purpose: The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor. Experimental design: We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis of in vitro expanded T-cell cultures. Parallel studies were performed on tumor-infiltrating lymphocytes (TIL) from 44 patients with metastatic melanoma.Results: Prominent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies from PDA patients. The notion that the tumor is a site of local T-cell expansion was strengthened by TCR deep-sequencing, revealing that the T-cell repertoire in the tumor is dominated by highly frequent CDR3 sequences that can be up to 10,000-fold enriched in tumor as compared to peripheral blood. In fact, TCR repertoire composition in PDA resembled that in melanoma. Moreover, in vitro expansion of TILs was equally efficient for PDA and melanoma, resulting in T-cell cultures displaying HLA class I-restricted reactivity against autologous tumor cells.Conclusions: The tumor-infiltrating T-cell response in PDA shows striking similarity to that in melanoma, where adoptive T-cell therapy has significant therapeutic impact. Our findings indicate that T-cell-based therapies may be used to counter disease recurrence in patients with resectable PDA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2016.1240859

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 100

Metadata

Authors
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., Loewer, M., Glimm, H., Hackert, T., Sprick, M. R., Höfer, T., Trumpp, A., Halama, N., Hassel, J. C., Strobel, O., Büchler, M., Sahin, U., & Offringa, R.
Venue
OncoImmunology
Published
2016-10-07
Volume
5
Issue
12
Pages
e1240859
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2529657929
Cited by
100
References
10
FWCI
4.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1080/2162402x.2016.1240859
The paper
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., Loewer, M., Glimm, H., Hackert, T., Sprick, M. R., Höfer, T., Trumpp, A., Halama, N., Hassel, J. C., Strobel, O., . . . Offringa, R. (2016). Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1240859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.